 A 24 WEEK, MULTICENTER, PROSPECTIVE, OPEN-LABELED, SINGLE-ARM, EXPLORATORY PHASE 4 CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LOBEGLITAZONE IN DECREASING INTRAHEPATIC FAT CONTENTS IN TYPE 2 DIABETES WITH NAFLD: 